Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.34 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245238 | 0.88 | BTK (0.40) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245338 | 0.88 | BTK (0.39) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245217 | 0.87 | BTK (0.41) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245325 | 0.86 | BTK (0.42) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245061 | 0.86 | JAK3 (0.39) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245006 | 0.86 | BTK (0.39) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245249 | 0.84 | BTK (0.38) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245368 | 0.83 | BTK (0.40) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL16245374 | 0.82 | BTK (0.40) | BTKJAK3EGFRNUDT14NUDT5 | |
| SCHEMBL15013573 | 0.81 | JAK3 (0.60) | JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | BTK 219/4885JAK3 1/4885EGFR 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.